Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes

Table 1 Baseline patient demographic and background characteristics (Asian population)

	Vildagliptin50 mg bid	Placebo
	n = 87	n = 86
Age, years	54.0 ± 8.4	54.9 ± 10.5
≥ 65, n (%)	8 (9.2)	13 (15.1)
Gender, female, n (%)	45 (51.7)	39 (45.3)
Race, n (%)
Indian (Indian subcontinent)	62 (71.3)	61 (70.9)
Chinese	24 (27.6)	24 (27.9)
Other	1 (1.1)	1 (1.2)
BMI, kg/m2	26.2 ± 3.0	26.7 ± 3.7
Body weight, kg	67.5 ± 9.5	68.8 ± 12.1
HbA1c, % (mmol/mol)	8.9 ± 1.0	9.0 ± 1.0
	(73.7 ± 10.9)	(74.8 ± 10.9)
FPG, mmol/L	9.1 ± 2.6	8.6 ± 2.5
T2DM duration, years	11.1 ± 6.4	12.1 ± 7.6
GFR, mL/min per 1.73 m2, n (%)
Normal, > 80	43 (49.4)	52 (60.5)
Mild, ≥ 50 to ≤ 80	42 (48.3)	33 (38.4)
Moderate, ≥ 30 to < 50	2 (2.3)	1 (1.2)
Background antidiabetic therapy
Insulin use at screening, n (%)
Intermediate-acting	21 (24.1)	20 (23.3)
Long-acting	14 (16.1)	8 (9.3)
Pre-mixed	52 (59.8)	58 (67.4)
Duration of insulin use, years	3.3 ± 2.9	3.9 ± 4.3
Daily dose of insulin, U	39.5 ± 15.8	39.5 ± 15.3
Daily number of insulin injections	1.9 ± 0.4	1.8 ± 0.4
Metformin use at screening, n (%)
Yes	52 (59.8)	52 (60.5)
No	35 (40.2)	34 (39.5)

Values are mean ± SD unless indicated otherwise. BMI: Body mass index; GFR: Glomerular filtration rate; FPG: Fasting plasma glucose; HbA1c: Hemoglobin A1c; T2DM: Type 2 diabetes mellitus.